Dr. Cindy Jacobs Addresses Key Smoking Cessation Issues
SEATTLE and VANCOUVER, British Columbia — Achieve Life Sciences, Inc. (Nasdaq: ACHV), known for its innovative approach in combating nicotine dependence, was represented by Dr. Cindy Jacobs, the President and Chief Medical Officer, at a recent high-profile public meeting organized by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). This meeting, centered around advancing smoking cessation efforts, took place on October 21, 2024.
Key Points from the FDA and NIH Meeting
The event was initiated by Robert Califf, M.D., the 25th Commissioner of the FDA, and featured various stakeholders including representatives from the FDA, NIH, and the National Institute on Drug Abuse. The primary focus was to explore innovative strategies that could facilitate faster development of treatments for smoking cessation.
During her presentation, Dr. Jacobs expressed gratitude for the FDA and NIH's initiative in bringing together experts dedicated to mitigating the health crises caused by smoking-related diseases. "It has been nearly two decades since a new prescription smoking cessation treatment has been approved by the FDA," remarked Dr. Jacobs. She emphasized that cytisinicline is currently the only one undergoing late-stage development in this field.
Significance of Cytisinicline
Dr. Jacobs shared compelling data from two Phase 3 clinical trials involving over 1,600 subjects, showcasing the efficacy and safety of cytisinicline, based on rigorous clinical endpoints of continuous smoking cessation. With a longer-term safety exposure study in progress, the company is optimistic about continuing its collaboration with the FDA as it prepares for a New Drug Application (NDA) submission.
History and Improvements of Cytisinicline
A focal point of Dr. Jacobs’s presentation was the historical context of cytisine as a smoking cessation aid, prevalent in Eastern and Central Europe for many years. While its efficacy was well documented, a complex 25-day titration schedule limited accessibility. Achieve Life Sciences has since revitalized this treatment into cytisinicline, featuring a new, streamlined dosing regimen and enhanced formulation. The results from completed Phase 3 trials exhibit promising safety and efficacy, affirming the potential of this innovative product.
Future Directions and Regulatory Engagement
In her closing remarks, Dr. Jacobs called for the FDA to revisit its drug approval processes for smoking cessation treatments. She highlighted that no new prescription medications had entered the market in nearly 20 years, raising concerns about the potential impact this might have on public health compared to the expedite approvals for other nicotine and tobacco products in the U.S.
The Broader Context of Smoking and Nicotine Use
As Achieve Life Sciences works tirelessly to address nicotine addiction, it's important to highlight the current statistics surrounding tobacco usage. In the United States alone, around 29 million adults and approximately 2.25 million school students smoke combustible cigarettes, underscoring the critical need for effective cessation therapies. Moreover, tobacco remains the primary cause of preventable death worldwide, claiming over eight million lives annually.
The advent of e-cigarettes has added to the challenge, with an estimated 11 million U.S. adults and 1.6 million students reportedly using these products. Currently, there are no FDA-approved treatments aimed specifically at assisting with quitting e-cigarettes, which further emphasizes the importance of cytisinicline.
Conclusion on Cytisinicline's Role in Public Health
Cytisinicline acts on the nicotinic acetylcholine receptor, which is crucial for alleviating the cravings and withdrawal symptoms associated with nicotine addiction. By engaging with these receptors, cytisinicline may lessen the pleasure derived from nicotine, making it a valuable tool for those aiming to quit smoking or using e-cigarettes. As an investigational product candidate, cytisinicline seeks to provide a fresh solution in the battle against nicotine dependence and is yet to receive approval from the FDA.
Frequently Asked Questions
What is cytisinicline?
Cytisinicline is a plant-based alkaloid being developed by Achieve Life Sciences as a treatment for nicotine addiction.
Who represented Achieve Life Sciences at the FDA meeting?
Dr. Cindy Jacobs, the President and Chief Medical Officer, represented Achieve Life Sciences.
What was the focus of the FDA and NIH public meeting?
The meeting focused on advancing smoking cessation treatments and fostering collaboration among experts in the field.
How many subjects were involved in the Phase 3 trials for cytisinicline?
Over 1,600 subjects participated in the two randomized Phase 3 clinical trials.
What are the implications of the recent FDA meeting for smoking cessation treatments?
The meeting highlighted the urgent need for effective smoking cessation treatments and ways to expedite the approval of new therapies like cytisinicline.
